One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Precigen, Inc.
PGEN · NMS · Healthcare · Biotechnology
Current price
$4.52
52-week range
$3.04 - $8.98
Market cap
$1.62B
Balance sheet
Distressed
-27.57x Concerning
Net debt $52.54M. Interest coverage shows how many times profit covers the interest bill.
What stands out
3 Rewards
1 Risk
3 rewards · 1 risks
- Reward Revenue grew 1520.6% last year.
- Reward Returns 38.8% on equity, ahead of 83% of its peers.
- Reward Trades at 41.1x P/E vs peer median 821.0x (95.0% cheaper).
- Risk Stock trades 278.5% above its 5-year average P/E.
What this company does
Precigen, Inc.
Precigen is a company that creates advanced medicines using gene and cell therapies, focusing on serious illnesses like cancer and autoimmune diseases. Their main income comes from developing these innovative treatments, which are then partnered with other drug companies or advanced through clinical trials, a process that can be costly but holds the promise of future profits if successful. This approach matters because it’s at the forefront of medical science, aiming to offer new hope for patients with few other options.
How the company got here
Precigen, Inc. was founded in 1998 as Intrexon Corporation, initially focusing on a broad range of applications in synthetic biology and genetic engineering. The company went public in 2013. A significant turning point occurred around 2019-2020 when Intrexon underwent a strategic pivot, narrowing its focus to human gene and cell therapies. This shift was accompanied by a name change to Precigen, Inc. in February 2020, reflecting its new, more concentrated direction in healthcare. The company's history is marked by a transition from a diverse biotechnology company to a more specialized biopharmaceutical entity.
What it actually does
Precigen is a biopharmaceutical company that develops advanced treatments called gene and cell therapies. These therapies use a company's own technology to target serious diseases, particularly in areas like cancer (immuno-oncology), autoimmune disorders (where the body's immune system attacks itself), and infectious diseases. The goal is to create new ways to treat illnesses that have limited options currently available.
AdenoVerse
The AdenoVerse platform is a key technology Precigen uses to create gene therapies. It involves using special delivery vehicles called adenovectors, which are like tiny biological couriers, to carry therapeutic genes into the body. These genes are designed to have a specific effect, such as fighting cancer cells or stimulating an immune response. Precigen is developing treatments for HPV-associated cancers and recurrent respiratory papillomatosis using this platform.
UltraCAR-T
UltraCAR-T is another core technology platform at Precigen, focused on developing cell therapies, specifically for cancer patients. This platform aims to engineer a patient's own T-cells (a type of immune cell) to better recognize and attack cancer cells. A key feature of UltraCAR-T is its focus on rapid and efficient manufacturing of these engineered cells, which can be crucial for timely treatment. Precigen is exploring UltraCAR-T for various blood cancers and solid tumors.
ActoBiotics
Precigen also has an ActoBiotics platform, which involves using engineered live microorganisms (like bacteria) as a way to deliver therapeutic agents. This approach is being explored for its potential in treating autoimmune disorders and other conditions. While a focus has shifted, this platform represents another facet of Precigen's diverse technological capabilities in developing novel therapies.
What management is betting on now
Precigen's current strategy is heavily focused on bringing its lead gene therapy candidate, PRGN-2012, for recurrent respiratory papillomatosis (RRP), towards commercialization. This involves preparing for regulatory submissions and ensuring manufacturing readiness for a potential launch. The company is also continuing development of its PRGN-2009 therapy for HPV-associated cancers. Management is prioritizing resources on these key programs, aiming to validate their technology platforms and establish a repeatable model for developing and launching advanced therapies.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-9.27M
FY2025 Q1
$-16.95M
FY2025 Q2
$-19.94M
FY2025 Q3
$-29.46M
FY2025 Q4
$-23.48M
FY2026 Q1
$-44.09M
FY2026 Q2
$-18.20M
FY2026 Q3
$11.45M
Revenue
$74.15M
Net income
$35.77M
Diluted EPS
0.08
Operating cash flow
$11.88M
Free cash flow
$11.45M
Fetching…
Sources
Revenue
$54.98M
Net income
$20.07M
Diluted EPS
0.05
Operating cash flow
$-17.81M
Free cash flow
$-18.20M
Fetching…
Sources
Revenue
$23.25M
Net income
$-7.93M
Diluted EPS
-0.02
Operating cash flow
$-43.83M
Free cash flow
$-44.09M
Fetching…
Sources
Revenue
$4.57M
Net income
$-23.50M
Diluted EPS
-0.04
Operating cash flow
$-23.46M
Free cash flow
$-23.48M
Fetching…
Sources
Revenue
$2.92M
Net income
$-146.34M
Diluted EPS
-1.06
Operating cash flow
$-29.07M
Free cash flow
$-29.46M
Fetching…
Sources
Revenue
$856.00K
Net income
$-26.64M
Diluted EPS
-0.09
Operating cash flow
$-18.98M
Free cash flow
$-19.94M
Fetching…
Sources
Revenue
$1.34M
Net income
$-54.15M
Diluted EPS
-0.18
Operating cash flow
$-16.32M
Free cash flow
$-16.95M
Fetching…
Sources
Revenue
$3.92M
Net income
$-19.73M
Diluted EPS
-0.05
Operating cash flow
$-8.24M
Free cash flow
$-9.27M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $4.52
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $52.5M. Interest coverage -27.6x.
Net debt
$52.54M
Interest coverage
-27.57x
Precigen, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
PGEN
BASELINE
Precigen, Inc.
Total debt $98.61M Interest coverage -27.57x This is the baseline the peer rows are being compared against.
Total debt $1.08B Interest coverage -17.25x Neither company has much profit cushion over interest right now.
Total debt $230.14M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $45.21M Interest coverage -38.64x Neither company has much profit cushion over interest right now.
Total debt $76.94M Interest coverage -192.50x Neither company has much profit cushion over interest right now.
What you should know
The case for and against PGEN
3 Rewards
1 Risk
Rewards
-
Revenue grew 1520.6% last year.
-
Returns 38.8% on equity, ahead of 83% of its peers.
-
Trades at 41.1x P/E vs peer median 821.0x (95.0% cheaper).
Risks
-
Stock trades 278.5% above its 5-year average P/E.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
41.09x
Forward P/E
-20.55x
P/B
19.32x
P/S
10.33x
EV/EBITDA
43.94x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
74.5%
Operating margin
52.1%
Net margin
15.6%
ROE
38.8%
ROA
11.0%
Health
Liquidity and balance-sheet strength
Debt / equity
1.18x
Current ratio
5.58x
Quick ratio
4.63x
Total debt
$98.61M
Total cash
$46.07M
Growth
How the business has been compounding
Revenue TTM
$156.94M
Revenue 5Y CAGR
-25.8%
EPS TTM
0.11
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-73.21M
Free CF TTM
$-89.83M
FCF margin
-57.2%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—